Prognostic value of metabolic tumor volume measured by 18F-FDG PET/CT in advanced-stage squamous cell carcinoma of the larynx and hypopharynx

Annals of Oncology

Volumn 24, Issue 1, 2013, Pages 208-214

  Park, G C ^a   Kim, J S ^b   Roh, J L ^b   Choi, S H ^b   Nam, S Y ^b   Kim, S Y ^b,c  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Korea Institute of Science and Technology   (South Korea)

Author keywords

laryngohypopharynx; Metabolic tumor volume; PET; prognostic factor; Squamous cell carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; TS 1; UNCLASSIFIED DRUG;

ADJUVANT CHEMORADIOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CONTROL; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EVALUATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; HYPOPHARYNX CARCINOMA; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; METABOLIC TUMOR VOLUME; OVERALL SURVIVAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; HYPOPHARYNGEAL NEOPLASMS; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84871565432     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds247     Document Type: Article

References (32)

1. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Harrison DFN. Classification: the great deception. J Otolaryngol 1988; 17: 12-15.
3. Bailey BJ. Beyond the 'new' TNM classification. Arch Otolaryngol Head Neck Surg 1991; 117: 369-370.
4. Piccirillo JF. Purposes, problems, and proposals for progress in cancer staging. Arch Otolaryngol Head Neck Surg 1995; 121: 145-149.
5. Halfpenny W, Hain SF, Biassoni L et al. FDG-PET. A possible prognostic factor in head and neck cancer. Br J Cancer 2002; 86: 512-516.
6. Wong RJ, Lin DT, Schöder H et al. Diagnostic and prognostic value of [(18)F] fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol 2002; 20: 4199-4208.
7. Ryan WR, Fee WE, Jr, Le QT et al. Positron-emission tomography for surveillance of head and neck cancer. Laryngoscope 2005; 115: 645-650.
8. Minn H, Lapela M, Klemi PJ et al. Prediction of survival with fluorine-18-fluorodeoxyglucose and PET in head and neck cancer. J Nucl Med 1997; 38: 1907-1911.
9. Allal AS, Dulguerov P, Allaoua M et al. Standardized uptake value of 2-[(18)F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol 2002; 20: 1398-1404.
10. Hermans R, Van den Bogaert W, Rijnders A et al. Value of computed tomography determined tumour parameters as outcome predictor of supraglottic cancer treated by definitive radiation therapy. Int J Radiat Oncol Biol Phys 1999; 44: 755-765.
11. Ljumanovi R, Langendijk JA, Schenk B et al. Supraglottic carcinoma treated with curative radiation therapy: identification of prognostic groups with MR imaging. Radiology 2004; 232: 440-448.
12. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors (RECIST Guidelines). J Natl Cancer Inst 2000; 92: 205-216.
13. Lee P, Weerasuriya DK, Lavori PW et al. Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys 2007; 69: 328-333.
14. Seol YM, Kwon BR, Song MK et al. Measurement of tumor volume by PET to evaluate prognosis in patients with head and neck cancer treated by chemoradiation therapy. Acta Oncol 2010; 49: 201-208.
15. Chung MK, Jeong HS, Park SG et al. Metabolic tumor volume of [18F]- fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer. Clin Cancer Res 2009; 15: 5861-5868.
16. Beitler JJ, Muller S, Grist WJ et al. Prognostic accuracy of computed tomography findings for patients with laryngeal cancer undergoing laryngectomy. J Clin Oncol 2010: 28: 2318-2322.
17. Worden FP, Moyer J, Lee JS et al. Chemoselection as a strategy for organ preservation in patients with T4 laryngeal squamous cell carcinoma with cartilage invasion. Laryngoscope 2009; 119: 1510-1517.
18. Knab RB, Salama JK, Solanki A et al. Functional organ preservation with definitive chemoradiation for T4 laryngeal squamous cell carcinoma. Ann Oncol 2008; 19: 1650-1654.
19. Wolf GT. Routine computed tomography scanning for tumor staging in advanced laryngeal cancer: implications for treatment selection. J Clin Oncol 2010; 28: 2315-2317.
20. Becker M, Zbaren P, Casselman JW et al. Neoplastic invasion of laryngeal cartilage: reassessment of criteria for diagnosis at MR imaging. Radiology 2008; 249: 551-559.
21. Castelijns JA, Van Den Brekel M, Tobi H et al. Laryngeal carcinoma after radiation therapy: correlation of abnormal MR imaging signal patterns in laryngeal cartilage with the risk of recurrence. Radiology 1996; 198: 151-155.
22. Haberkorn U, Strauss LG, Reisser C et al. Glucose uptake, perfusion, and cell proliferation in head and neck tumors: relation of positron emission tomography to flow cytometry. J Nucl Med 1991; 32: 1548-1555.
23. Minn H, Clavo AC, Grenman R et al. In vitro comparison of cell proliferation kinetics and uptake of tritiated fluorodeoxyglucose and L-methionine in squamous-cell carcinoma of the head and neck. J Nucl Med 1995; 36: 252-258.
24. Minn H, Joensuu H, Ahonen A et al. Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors. Cancer 1988; 61: 1776-1781.
25. Bos R, van Der Hoeven JJ, van Der Wall E et al. Biologic correlates of (18) fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 2002; 20: 379-387.
26. Vesselle H, Schmidt RA, Pugsley JM et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res 2000; 6: 3837-3844.
27. La TH, Filion EJ, Turnbull BB et al. Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2009; 74: 1335-1341.
28. Higgins KA, Hoang JK, Roach MC et al. Analysis of pretreatment FDG-PET CUV parameters in head-and-neck cancer: tumor SUVmean has superior prognostic value. Int J Radiat Oncol Biol Phys 2012; 82: 548-553.
29. Allal AS, Slosman DO, Kebdani T et al. Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro- 2-deoxy- D-glucose. Int J Radiat Oncol Biol Phys 2004; 59: 1295-1300.
30. Torizuka T, Tanizaki Y, Kanno T et al. Prognostic value of 18F-FDG PET in patients with head and neck squamous cell cancer. AJR Am J Roentgenol 2009; 192: W156-W160.
31. Roh JL, Pae KH, Choi SH et al. 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography as guidance for primary treatment in patients with advanced stage resectable squamous cell carcinoma of the larynx and hypopharynx. Eur J Surg Oncol 2007; 33: 790-795.
32. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.